<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613846</url>
  </required_header>
  <id_info>
    <org_study_id>16037 / AN 33/11</org_study_id>
    <secondary_id>2011-004396-36</secondary_id>
    <nct_id>NCT01613846</nct_id>
    <nct_alias>NCT02083094</nct_alias>
  </id_info>
  <brief_title>Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)</brief_title>
  <official_title>Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <brief_summary>
    <textblock>
      Sorafenib and pazopanib are both effective and promising treatments for advanced Renal Cell
      Carcinoma (RCC). Both drugs are registered for this indication. No prospective comparative
      data in advanced RCC (or other indications) have been published. A search in the
      clinicaltrials.gov database did not reveal any planned or ongoing studies. As sequential
      therapy is now the standard of treatment for advanced RCC it is important to evaluate in
      clinical trials what the value of different sequential strategies is. This needs to be done
      every time new agents are introduced into the treatment armamentarium. As there are no data
      yet on the sequential use of sorafenib followed by pazopanib or vice versa, this sequence,
      however, will most certainly be used in daily practice, it is required to examine efficacy
      and safety of this sequential approach in a clinical trial in a randomized setting.

      Therefore, the investigators have designed an open randomized study in patients not
      previously treated for advanced RCC. Suitable patients will be randomized (1:1) in 2 groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Actual">October 30, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate if progression-free survival from randomization to progression or death during second-line therapy (Total PFS) of sorafenib followed by pazopanib is non-inferior compared to pazopanib followed by sorafenib.</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to progression during second-line therapy (total TTP)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first-line treatment failure (progression, death, discontinuation due to toxicity) descriptively in each arm</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS in first-line and second-line treatment, descriptively</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival, descriptively (data cut-off same as for primary endpoint</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR); Response rates in first-line and in second-line (CR, PR, SD according to RECIST criteria)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (FACIT-F, FKSI-10)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker programme</measure>
    <time_frame>4 years</time_frame>
    <description>Circulating tumor cells, Single Nucleotide Polymorphisms, Serum Protein Signatures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>4 years</time_frame>
    <description>Monitoring of adverse events, summaries and listings of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">544</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib followed by pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib 400 mg bid orally until progression or intolerable toxicity, followed by pazopanib 800 mg once daily orally until progression or intolerable toxicity.
During first- and second-line, treatment visits are scheduled in weeks 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pazopanib followed by Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pazopanib 800 mg once daily orally until progression or intolerable toxicity, followed by Sorafenib 400 mg bid orally until progression or intolerable toxicity:
During first- and second-line, treatment visits are scheduled in weeks, 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib+Pazopanib</intervention_name>
    <description>Sorafenib (first-line) followed by Pazopanib (second-line)</description>
    <arm_group_label>Sorafenib followed by pazopanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib+Sorafenib</intervention_name>
    <description>Pazopanib (first-line) followed by Sorafenib (second-line)</description>
    <arm_group_label>Pazopanib followed by Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with metastatic / advanced RCC (all histologies), who are not suitable for
             cytokine therapy and for whom study medication constitutes first-line treatment. For
             cytokine- unsuitability at least one of the following criteria must be fulfilled*:

               -  Age 66 to 88 years

               -  Non-clear cell histology RCC

               -  Intermediate risk according to MSKCC score

               -  ECOG ≥ 1 and&gt; 1 organ metastasis + &lt; 24 months between diagnosis and establishing
                  indication for interleukin-2-therapy

               -  ECOG ≥ 1 and &quot;unable to carry on normal activity or do active work&quot; (Karnofsky
                  Index 70%)

               -  Creatinine ≥ 1x ULN and &lt; 2x ULN

               -  Total bilirubin ≥ 1x ULN and &lt; 1.5x ULN

               -  Present autoimmune disease

               -  Patients who might require steroids

               -  Hypersensitivity against cytokines

               -  Severe organic disease, not interfering with other in-/exclusion criteria of the
                  Switch-2 study

               -  Non-symptomatic brain metastases

               -  Severe lung disease (e.g. PAH, COPD) with Pa O2 &lt; 60 mmHg on rest

          2. Age ≥ 18 and ≤ 85 years

          3. Karnofsky Index ≥ 70% (see appendix 15.1)

          4. MSKCC prognostic score (2004), low or intermediate (see appendix 15.2)

          5. Life expectancy of at least 12 weeks

          6. Subjects with at least one uni-dimensional (for RECIST 1.1) measurable lesion. Lesions
             must be measured by CT/MRI- scan

          7. Adequate bone marrow, liver and renal function as assessed by the following laboratory
             requirements to be conducted within 7 days prior to start of therapy:

               -  hemoglobin &gt; 9.0 g/dl

               -  absolute neutrophil count (ANC) &gt; 1,500 µl

               -  Platelet count ≥ 100,000 / µl

               -  total bilirubin &lt; 1.5x the upper limit of normal (Note: Subjects with Gilbert'
                  Syndrome are eligible if their total bilirubin is &lt; 3.0 X ULN and direct
                  bilirubin ≤ 35 %).

               -  ALAT and ASAT &lt; 2.5x upper limit of normal (Note: concomitant elevations in
                  bilirubin ans ASAT/ALAT above 1.0x upper limit of normal are not permitted).

               -  Alkaline phosphatase &lt; 4x upper limit of normal

               -  PT-INR/aPTT &lt; 1.2x upper limit of normal (Patients who are being therapeutically
                  anticoagulated with an agent such as coumadin or heparin will be allowed to
                  participate provided that their INR is stable and within the recommended range
                  for the desired level of anticoagulation and no prior evidence of underlying
                  abnormality in these parameters exists).

               -  Serum creatinine &lt; 2x upper limit of normal

          8. Written Informed Consent

        Exclusion Criteria:

          1. History of cardiac disease: congestive heart failure &gt; NYHA class 2 or with LVEF at
             baseline echocardiography &lt; 50%, (echocardiography is optional); active CAD (MI more
             than 6 months prior to study entry is allowed); cardiac arrhythmias requiring
             anti-arrhythmic therapy (beta blockers or digoxin are permitted)

          2. Uncontrolled hypertension (defined as blood pressure ≥ 150 mmHg systolic and/or ≥ 90
             mmHg diastolic on medication).

          3. History of HIV infection or chronic hepatitis B or C

          4. 4. Active clinically serious infections (&gt; grade 2 NCI-CTC version 4.03)

          5. Symptomatic metastatic brain or meningeal tumors (unless the patient is &gt; 6 months
             from definitive therapy, has a negative imaging study within 4 weeks of study entry
             and is clinically stable with respect to the tumor at the time of study entry)

          6. Patients with seizure disorder requiring medication (such as steroids or
             anti-epileptics)

          7. Patients with evidence or history of bleeding diathesis

          8. History of organ allograft

          9. Major surgery within 4 weeks of start of study

         10. Autologous bone marrow transplant or stem cell rescue within 4 months before study
             start.

         11. Any significant condition that increases the risk for bleeding, including, but not
             limited to active peptic ulcer disease, inflammatory bowel disease, known intraluminal
             or endobronchial metastatic lesions and/or lesions infiltrating major pulmonary
             vessels with risk of bleeding, presence of non-healing wound or trauma within 4 weeks
             prior to first dose of investigational drug

         12. History of cerebrovascular accident including transient ischemic attack (TIA),
             pulmonary embolism or untreated deep vein thrombosis (DVT) within the past 6 months
             (Note: Subjects with recent DVT who have been treated with therapeutic
             anti-coagulating agents for at least 6 weeks are eligible)

         13. Corrected QT Interval (QTc) &gt; 480 msecs

         14. Untreated hypothyroidism

         15. Patients undergoing renal dialysis

         16. Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal
             cell carcinoma, superficial bladder tumors [Ta, Tis &amp; T1] or any cancer curatively
             treated &gt; 3 years prior to study entry

         17. Pregnant or breast-feeding patients. Women of childbearing potential must have a
             negative pregnancy test performed within 7 days of the start of treatment. Both men
             and women enrolled in this trial must use adequate barrier birth control measures
             (with a Pearl Index &lt; 1) during the course of the trial and 3 months after the
             completion of trial

         18. Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results

         19. Any condition that is unstable or could jeopardize the safety of the patient and their
             compliance in the study

         20. Patients unable to swallow oral medications

         21. Clinically significant gastrointestinal abnormalities that may affect absorption of
             investigational product

         22. Known allergy to Votrient or Nexavar (i.e. to active substance or one of the
             constituents)

         23. Prior exposure to study drugs.

         24. Investigational drug therapy within 4 weeks of study entry.

         25. Use of biologic response modifiers, such as G-CSF and other hematopoietic growth
             factors, within 3 weeks of study entry

         26. Radiotherapy within 3 weeks of start of study drug and planned radiotherapy during the
             study

         27. Concomitant medication: Any condition at the discretion of the investigator that
             precludes compliance with concomitant therapy restrictions described below.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen E. Gschwend, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum rechts der Isar, TU München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. ö. Bezirkskrankenhaus Kufstein</name>
      <address>
        <city>Kufstein</city>
        <zip>6330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Linz GmbH</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, Urologische Klinik</name>
      <address>
        <city>Aachen</city>
        <zip>51074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesundheitszentrum St. Marien GmbH</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Urologie</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Virchow Klinikum / Klein. Für Innere Med / Onkologie/Hämatologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Pott / Tirier / Hannig - Onkologie</name>
      <address>
        <city>Bottrop</city>
        <zip>46236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie im Schlosscarrée Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38100</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethanien Krankenhaus Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis Dörfel/Göhler</name>
      <address>
        <city>Dresden</city>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Duisburg</city>
        <zip>47179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Düren gGmbH</name>
      <address>
        <city>Düren</city>
        <zip>52351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie Neandertal - Ortsübergreifende Gemeinschaftspraxis für Urologie</name>
      <address>
        <city>Erkrath</city>
        <zip>40699</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waldkrankenhaus St. Marien</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Antonius-Hospital in Eschweiler / Klinik f. Hämatologie und Onkologie</name>
      <address>
        <city>Eschweiler</city>
        <zip>52249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämato-onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Freiberg</name>
      <address>
        <city>Freiberg</city>
        <zip>09599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für interdisziplinäre Onkologie &amp; Hämatologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Osthessen GmbH</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gem.praxis Dres. J. Wilke, H. Wagner - Hämatol.u.intern.Onkol. am Klinikum Fürth</name>
      <address>
        <city>Fürth</city>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Goslar</city>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius-Hospital Gronau GmbH</name>
      <address>
        <city>Gronau</city>
        <zip>48599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Klinik für Urologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie-Heinsberg</name>
      <address>
        <city>Heinsberg</city>
        <zip>52525</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis</name>
      <address>
        <city>Hildesheim</city>
        <zip>331135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Urologie</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Überörtliche Gemeinschaftspraxis</name>
      <address>
        <city>Köln</city>
        <zip>50968</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Urologie</name>
      <address>
        <city>Lauenburg</city>
        <zip>21481</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Leer - Emden</name>
      <address>
        <city>Leer</city>
        <zip>26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Mitte/ MVZ Delitzsch GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Facharztpraxis</name>
      <address>
        <city>Lutherstadt Eisleben</city>
        <zip>06295</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg A.ö.R</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philips-Universität-Marburg, Urologie und Kinderurologie</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Markkleeberg</name>
      <address>
        <city>Markkleeberg</city>
        <zip>04416</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PUR/R Praxisklinik Urologie Rhein Rhur</name>
      <address>
        <city>Mühlheim</city>
        <zip>45458</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum r. d. Isar, Klinik für Urologie</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster , Klinik für Urologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eps- early phase solutions GmbH</name>
      <address>
        <city>Pößneck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas Krankenhaus St. Josef</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Urologie und Onkologie</name>
      <address>
        <city>Rostock</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakoniekrankenhaus Rotenburg (Wümme) gGmbH</name>
      <address>
        <city>Rotenburg (Wümme)</city>
        <zip>27356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Sindelfingen-Böblingen</name>
      <address>
        <city>Sindelfingen</city>
        <zip>71065</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital / Innere Med III Onko Hämato Palliativm</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eberhard-Karls-Universität Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie und internistische Onkologie</name>
      <address>
        <city>Velbert</city>
        <zip>42551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nordoberpfalz AG</name>
      <address>
        <city>Weiden</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesellsch. z. Förd. Von Wissenschaft u.Qualitätssicherung i.d.ambul.Onkologie</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft für Onkologie und Urologie</name>
      <address>
        <city>Wilhelmshaven</city>
        <zip>26389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Urologie</name>
      <address>
        <city>Wuppertal</city>
        <zip>42103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf Gasthuis</name>
      <address>
        <city>Delft</city>
        <zip>2600 AG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HAGA</name>
      <address>
        <city>Den Haag</city>
        <zip>2545</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2130 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TweeSteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VieCuri Medical Center</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

